|Bid||10.43 x 1200|
|Ask||11.00 x 1200|
|Day's Range||10.38 - 10.70|
|52 Week Range||9.47 - 30.75|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.45|
16, 2022 // 10 pm CET (4 pm EST; 9 pm GMT)Nov. 17, 2022 // 2 pm CET (8 am EST; 1 pm GMT)Annual General MeetingMay 18, 2022For a direct import of the dates to your calendar, please visit our corporate website: https://www.
My name is Julia Neugebauer, Senior Director, Investor Relations of MorphoSys and it is my pleasure to welcome you to our third quarter 2021 financial results conference call. Joining me on the call today are Jean-Paul Kress, Chief Executive Officer; Sung Lee, Chief Financial Officer; and Malte Peters, Chief Research and Development Officer.
6 million), 22% growth Q-Q * Ten abstracts, including two oral presentations, accepted at upcoming ASH * Pelabresib data for arm 3 of MANIFEST study to be presented at ASH confirm prior data * Felzartamab demonstrated proof-of-concept in patients with aMN at Kidney WeekPLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 11, 2021 / MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports financial results for the third quarter and the first nine months of 2021."Monjuvi sales continued to build momentum in the